Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q14318

UPID:
FKBP8_HUMAN

ALTERNATIVE NAMES:
38 kDa FK506-binding protein; FK506-binding protein 8; FKBPR38; Rotamase

ALTERNATIVE UPACC:
Q14318; C8C9T5; Q53GU3; Q7Z349; Q86YK6

BACKGROUND:
The 38 kDa FK506-binding protein, or FKBP8, serves as a constitutively inactive peptidyl-prolyl cis-trans isomerase that becomes active upon binding to calmodulin and calcium. It acts as a chaperone for BCL2, targeting it to mitochondria and affecting its phosphorylation, which is crucial for apoptosis regulation. The formation of a complex between BCL2, FKBP8, calmodulin, and calcium suggests a significant role in preventing BCL2 from binding to its targets, thereby influencing cell death pathways. FKBP8's involvement in the inhibition of influenza A virus infection further underscores its potential in antiviral defense mechanisms.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of FK506-binding protein 8 offers promising avenues for the development of novel therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.